Alzheon
111 Speen Street, Suite 306
Framingham
Massachusetts
01701
United States
Tel: 508-861-7709
Fax: 508-861-1500
Website: http://www.alzheon.com/
Email: info@alzheon.com
About Alzheon
At Alzheon, we apply a precision medicine approach utilizing our scientific knowledge and clinical expertise to make advances in the challenging field of therapeutics for Alzheimer’s and other neurological disorders. Our efforts have resulted in ALZ-801, a novel, investigational medicine with an ideal profile for Alzheimer’s patients: an oral pill with favorable safety and the ability to interfere with the amyloid pathology that leads to Alzheimer’s disease.
107 articles about Alzheon
-
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
-
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
8/17/2020
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker Results
-
Martin Tolar, chief executive officer of Alzheon, told BioSpace that his company’s drug was designed to inhibit the formation of toxic soluble amyloid oligomers.
-
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
1/7/2020
Alzheon, Inc. announced that Christopher Noel Dunn, Jordan Heller, and Diane K. Jorkasky, MD, FACP, have been appointed to the company’s board of directors.
-
Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning
1/7/2020
Industry veteran brings broad commercial expertise in neuroscience drug development and commercialization as Alzheon advances ALZ-801 into Phase 3 as potentially the first oral disease-modifying treatment for Alzheimer’s disease
-
Alzheon Announces Scientific Presentation at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Taking Place on December 4-7 in San Diego, USA
12/2/2019
Cortical Thickness May Be a Useful Biomarker in Future Disease Modification Trials with High-Risk APOE4/4 Alzheimer’s Patients
-
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
11/6/2019
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course
-
A 2013 study that analyzes IPO withdrawals between 1999 and 2004 found that about 13 percent returned later for a successful IPO, 36 percent turned again to raising capital privately, and 42 percent either merged or were acquired by other companies—another common strategy for biotechs. And about ...
-
Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.
-
The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange.
-
Alzheon Takes Another Shot at an IPO
8/28/2018
In April, Alzheon attempted an initial public offering (IPO) to raise $80 million, but withdrew the offering. It has decided to try again, filing with the U.S. Securities and Exchange Commission (SEC), indicating it planned to raise $40 million in an IPO. -
Alzheon Scientists Discover Endogenous Substance in Human Brain That Inhibits Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease
8/6/2018
Publication Details Discovery of 3-Sulfopropanoic Acid, the Primary Metabolite of Tramiprosate and its Prodrug ALZ-801, in Cerebrospinal Fluid of Healthy Subjects as well as Alzheimer’s Patients
-
Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors
8/6/2018
Mr. Flanzraich was an early investor in Alzheon and served in the role of Chief Business Officer of Alzheon as a consultant to the company from February to May 2018.
-
Alzheon Researchers Identify Brain Molecule that Inhibits Formation of Alzheimer’s Proteins
8/6/2018
Scientists with Framingham, Massachusetts-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid, the primary driver of Alzheimer’s disease. The substance is 3-sulfopropanoic acid (3-SPA). -
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801
7/23/2018
Presentation at the Alzheimer’s Association International Conference Details Patient Responder Analyses on Key Clinical Outcomes.
-
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
-
Alzheon to Make Presentations at Upcoming Industry and Investor Conferences
5/22/2018
Keynote at Drug Discovery Innovation Programme and Company Presentation at JMP Securities Life Sciences Conference
-
Are All Cancers Rare Cancers?
5/1/2018
Biopharmaceutical companies are focusing their drugs for smaller and smaller and more clearly delineated patient populations. No longer is a drug for lung cancer or even non-small cell lung cancer, but a much smaller segment. -
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
-
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.